Leleu I, Penaud B, Blumen-Ohana E, Rodallec T, Adam R, Laplace O, Akesbi J, Nordmann J-P
Centre hospitalier national d'ophtalmologie des 15-20, 28, rue de Charenton, 75012 Paris, France.
Centre hospitalier national d'ophtalmologie des 15-20, 28, rue de Charenton, 75012 Paris, France.
J Fr Ophtalmol. 2018 Nov;41(9):789-801. doi: 10.1016/j.jfo.2018.03.014. Epub 2018 Oct 19.
We report cases of delayed, sustained elevated intraocular pressure (IOP) associated with repeated intravitreal anti-VEGF injections (IVI), which ultimately resulted in the need for filtering surgery. Two of the three cases demonstrated severe IOP elevation despite maximal medical treatment following unilateral IVI and required urgent filtering surgery. Optic nerve involvement was severe in all three cases. These intravitreal injections were performed for exudative age-related macular degeneration (AMD), and the patients did not show any sign of glaucoma or ocular hypertension prior to the initiation of treatment. Elevated IOP secondary to intravitreal steroids is a well-known side effect, as is immediate transient IOP elevation associated with anti-VEGF injection. Late, sustained IOP elevation after repeated injections of anti-VEGF, described approximately ten years ago, is often underestimated. Its incidence is estimated between 2.1% and 13% according to studies and increases with the number of IVI (cumulative effect). The pathophysiologic process is becoming increasingly understood, and several risk factors for this chronic IOP elevation have been identified. Most often, it is a moderate IOP elevation for which topical monotherapy is sufficient, or sometimes two, three or four medications or even selective laser trabeculoplasty (SLT). However, filtering surgery may rarely be required. Our findings illustrate a little-described phenomenon: a sudden, severe, late IOP elevation in response to anti-VEGF by an "overflow" effect, requiring urgent filtering surgery.
我们报告了与重复玻璃体内抗血管内皮生长因子注射(IVI)相关的延迟性、持续性眼内压(IOP)升高的病例,最终导致需要进行滤过手术。三例中的两例在单侧IVI后尽管进行了最大程度的药物治疗仍出现严重的IOP升高,并需要紧急滤过手术。所有三例均有严重的视神经受累。这些玻璃体内注射是针对渗出性年龄相关性黄斑变性(AMD)进行的,患者在治疗开始前未表现出任何青光眼或高眼压的迹象。玻璃体内注射类固醇导致的IOP升高是一种众所周知的副作用,抗血管内皮生长因子注射相关的即刻短暂IOP升高也是如此。大约十年前描述的重复注射抗血管内皮生长因子后出现的晚期、持续性IOP升高常常被低估。根据研究,其发生率估计在2.1%至13%之间,并随着IVI次数的增加而升高(累积效应)。其病理生理过程越来越为人所理解,并且已经确定了这种慢性IOP升高的几个危险因素。大多数情况下,是轻度的IOP升高,局部单一疗法就足够了,有时需要两种、三种或四种药物,甚至选择性激光小梁成形术(SLT)。然而,很少需要进行滤过手术。我们的研究结果说明了一种很少被描述的现象:由于“溢出”效应,对抗血管内皮生长因子出现突然、严重的晚期IOP升高,需要紧急滤过手术。